Ronald Levy: A Pioneer in Cancer Immunotherapy at Stanford University

Dr. Ronald Levy, Professor of Medicine at Stanford University, has revolutionized cancer treatment through his pioneering work in harnessing the immune system to fight malignancies. His groundbreaking research has led to the development of novel immunotherapies, most notably monoclonal antibodies, which have significantly improved the survival rates of millions of people with lymphoma and other cancers.

Early Career and Influences

Dr. Levy's fascination with the immune system began early in his medical career and deepened during his formative research experiences. He worked in Michael Feldman’s lab at the Weizmann Institute in Israel, at NIH with Steven Rosenberg, and again at Weizmann with Michael Sela. His time at Weizmann was marked by the Six-Day War and the Yom Kippur War. Despite these challenges, he succeeded in conducting groundbreaking research and meeting his future wife, Shoshana, who is now also a researcher at Stanford.

Even when cancer cells often fail to trigger internal defense mechanisms, Dr. Levy remained convinced that the body’s own defenses could be used to fight cancer. Upon his return to Stanford, his work intensified after Kohler and Milstein produced the first hybridomas, which immortalized antibody-producing cells and ensured a steady stream of identical antibodies.

Breakthrough with Monoclonal Antibodies

In 1981, Dr. Levy opened the field of monoclonal antibody therapy for cancer. He demonstrated that antibodies could be custom-made for each patient with lymphoma. His first patient was treated successfully and lived for over 35 years free of his lymphoma. This achievement marked a turning point in cancer treatment, paving the way for a new era of targeted therapies.

Development of Rituximab

Dr. Levy played a crucial role in the development of Rituximab, the first monoclonal antibody approved by the FDA for cancer treatment. Rituximab, which entered the market in 1997, targets the CD20 protein found on B-cell lymphoma cells. The drug proved successful in approximately half of the patients to whom it was given, resulting in tumor regression with very few side effects. Rituximab has since become a standard treatment for various B-cell lymphomas and has significantly improved patient outcomes worldwide.

In Situ Therapeutic Vaccination

Most recently, Dr. Levy and his group have been exploring a novel approach called in situ therapeutic vaccination. This involves injecting immune-enhancing antibodies directly into the tumor to activate the local immune system, enabling it to fight cancer throughout the body. This strategy aims to stimulate a systemic anti-tumor response by converting the tumor into an "in situ" vaccine.

Current Research Focus

Dr. Levy is currently studying non-responding lymphoma cells that become more prevalent as patients undergo treatment. He believes this cell subpopulation may constitute the tumor’s stem cell population. By understanding the mechanisms that drive resistance to therapy, Dr. Levy hopes to develop new strategies to overcome these challenges and improve treatment outcomes for all patients with lymphoma.

His research concentrates on the study of malignant lymphoma and tumors of the immune system using the tools of immunology and molecular biology to develop a better understanding of the initiation and progression of the malignant process. Receptor molecules present on the surface of tumor cells transmit signals for regulation of cell growth. These receptors include the immunoglobulin molecule on B cell tumors and the T cell receptor on T cell tumors. Questions the lab is currently addressing include:

Can a clue to the pathogenesis of lymphoma be derived from a study of their antigen receptors?
Can new treatments for lymphoma be developed by targeting receptors with monoclonal antibodies?
To characterize the molecular and cell biology of the tumor cells in lymphoma.

Clinical Trials and Therapeutic Approaches

Dr. Levy's research has led to the development of several clinical trials evaluating novel immunotherapeutic approaches for lymphoma. These trials often involve personalized active immunotherapy, an attempt to use a person's own immune system to combat disease. Some notable examples include:

Phase Ib/II trial of TLR9 agonist SD-101 with ibrutinib and radiation therapy: This trial studies the side effects and best dose of toll-like receptor 9 (TLR9) agonist SD-101 when given together with ibrutinib and radiation therapy and to see how well they work in treating patients with Low Grade Follicular Lymphoma, Marginal Zone Lymphoma, or Mantle Cell Lymphoma that has come back after a period of improvement or no longer responds to treatment.
Trial of anti-OX40 antibody BMS-986178 with TLR9 agonist SD-101 and radiation therapy: This phase I trial studies the side effects and best dose of the anti-OX40 antibody BMS-986178 when given together with the TLR9 agonist SD-101 and radiation therapy in treating patients with low-grade B-cell Non-Hodgkin lymphomas.
Trial of VTX-2337 with radiation therapy: This study is to determine the safety and effectiveness of VTX-2337 (an investigational drug that stimulates the immune system) in combination with radiation therapy in treating patients with low-grade B-cell lymphoma.
Trial of intratumoral CpG injections with local radiation in mycosis fungoides: This is a single institution phase I / II trial to evaluate the safety and efficacy of intratumoral CpG injections combined with local radiation in patients with mycosis fungoides.

Addressing Mantle Cell Lymphoma

Mantle cell lymphoma (MCL) is a sub-type of non-Hodgkin's lymphoma (NHL) which is generally considered incurable with current therapy. Treatment includes high-dose chemotherapy followed by stem cell transplant, which eliminates most of the lymphoma, but temporarily wipes out a patient’s immune system. Even with this aggressive therapy, residual lymphoma cells remain and cause the patients to recur within a few years. Participants in some trials will receive an autologous vaccine against their individual lymphoma after undergoing stem cell transplantation. Eligible patients may initiate oral therapy with idelalisib, continuing for up to twelve 28-day cycles.

Read also: Parking at UCLA Westwood

Molecular Insights into Follicular Lymphoma

Research has also focused on the molecular characteristics of follicular lymphoma (FL). An early event in the genesis of follicular lymphoma (FL) is the acquisition of new glycosylation motifs in the B cell receptor (BCR) due to gene rearrangement and/or somatic hypermutation. These N-linked glycosylation motifs (N-motifs) contain mannose-terminated glycans and can interact with lectins in the tumor microenvironment, activating the tumor BCR pathway. N-motifs are stable during FL evolution suggesting that FL tumor cells are dependent on them for their survival. Studies have investigated the dynamics and potential impact of N-motif prevalence in FL at the single cell level across distinct tumor sites and over time.

Overcoming Immunotherapy Resistance

Spontaneous tumors that arise in genetically engineered mice recapitulate the natural tumor microenvironment and tumor-immune coevolution observed in human cancers, providing a more physiologically relevant preclinical model relative to implanted tumors. Similar to many cancer patients, oncogene-driven spontaneous tumors are often resistant to immunotherapy, and thus novel agents that can effectively promote antitumor immunity against these aggressive cancers show considerable promise for clinical translation, and their mechanistic assessment can broaden our understanding of tumor immunology. Research has explored how tumor-targeted TLR9 stimulation remodels the microenvironment of spontaneously arising tumors during an effective antitumor immune response.

Honors and Recognition

Dr. Levy's contributions to cancer research have been widely recognized throughout his career. Some of his notable awards and honors include:

2016 AACR-CRI Lloyd J. Old Award in Cancer Immunology
2016 Outstanding Investigator Award, National Cancer Institute
2009 King Faisal International Prize for Science, King Faisal Foundation
2008 Elected Member, National Academy of Sciences, Washington, D.C.
2007 Elected Member, Institute of Medicine
2007 de Villiers International Achievement Award, Leukemia and Lymphoma Society
2004 Dameshek Prize, American Society of Hematology
2003 Jeffrey A. Gottlieb Memorial Award, MD Anderson Cancer Center
2001 Evelyn Hoffman Memorial Award, Lymphoma Research Foundation of America
2000 C. Chester Stock Award Lectureship, Memorial Sloan-Kettering Cancer Center
1999 David A. Karnofsky Memorial Award and Lecture, ASCO
1999 Charles F. Kettering Prize, General Motors Cancer Research Foundation
1997 AACR-Joseph H. Burchenal Memorial Award

Read also: Education Reform under Reagan

tags: #Ronald #Levy #Stanford #University #research